DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Rick Gonzalez, Chief Executive Officer, will participate at the annual LD Micro Conference, being held December 2-4, 2014 in Los Angeles, CA. Mr. Gonzalez will present a Company update on Thursday, December 4, 2014 at 8:30 AM PT.
Investors and the public are invited to view the live webcast of Mr Gonzalez’s presentation at http://wsw.com/webcast/ldmicro7/navb. Following the conference, the webcast will be archived for approximately 30 days.
Attending investors who would like to schedule a meeting with Navidea during the conference may do so by contacting Navidea directly or using the 1-on-1 meeting request on the LD Micro conference website.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms including Manocept™, NAV4694, NAV5001, and NAV1800 (RIGScan™), to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and by the EMA in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapies advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.